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Abstract
Aging leads to increased cellular senescence and is associated with decreased
potency of tissue‐specific stem/progenitor cells. Here, we have done an extensive
analysis of cardiac progenitor cells (CPCs) isolated from human subjects with cardio-
vascular disease, aged 32–86 years. In aged subjects (>70 years old), over half of
CPCs are senescent (p16INK4A, SA‐β‐gal, DNA damage γH2AX, telomere length,
senescence‐associated secretory phenotype [SASP]), unable to replicate, differenti-
ate, regenerate or restore cardiac function following transplantation into the
infarcted heart. SASP factors secreted by senescent CPCs renders otherwise healthy
CPCs to senescence. Elimination of senescent CPCs using senolytics abrogates the
SASP and its debilitative effect in vitro. Global elimination of senescent cells in aged
mice (INK‐ATTAC or wild‐type mice treated with D + Q senolytics) in vivo activates
resident CPCs and increased the number of small Ki67‐, EdU‐positive cardiomy-
ocytes. Therapeutic approaches that eliminate senescent cells may alleviate cardiac
deterioration with aging and restore the regenerative capacity of the heart.
K E YWORD S
ageing, cardiac regeneration, cardiac repair, myocardial infarction, p16INK4a, progenitor cells,
senescence, senolytics, senescence‐associated secretory phenotype
1 | INTRODUCTION
Aging is the greatest risk factor for many life‐threatening disorders,
including cardiovascular diseases, neurodegenerative diseases, cancer
and metabolic syndromes (St Sauver et al., 2015). Aging leads to
increased cellular senescence in a number of tissues and is fre-
quently associated with increased expression of the senescence bio-
marker, p16Ink4a (also known as Cdkn2a), resistance to apoptosis,
and impaired proliferation and tissue regeneration (Jeyapalan &
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Sedivy, 2008; Krishnamurthy et al., 2004; Sharpless & DePinho,
2007). Senescent cells disrupt tissue structure and function through
their senescence‐associated secretory phenotype (SASP), consisting
of pro‐inflammatory cytokines, chemokines, ECM‐degrading proteins
and other factors, which have deleterious paracrine and systemic
effects (Tchkonia, Zhu, Deursen, Campisi, & Kirkland, 2013; Xu, Pal-
mer, et al., 2015; Xu, Tchkonia, et al., 2015). Remarkably, even a rel-
atively low abundance of senescent cells (10%–15% in aged
primates) is sufficient to cause tissue dysfunction (Herbig, Ferreira,
Condel, Carey, & Sedivy, 2006; Xu et al., 2018).
To test whether senescent cells are causally implicated in age‐
related dysfunction and whether their removal is beneficial, J. L.
Kirkland, T. Tchkonia, J. van Deursen (Mayo), D. Baker (Mayo) and
colleagues made use of a promoter for the biomarker for senes-
cence, p16INK4a, and an inducible “suicide” gene designed by P.
Scherer et al. (Pajvani et al., 2005) to develop a novel transgene,
INK‐ATTAC, to permit inducible elimination of p16INK4a‐positive
senescent cells upon administration of a drug (AP20187) (Baker
et al., 2011). In these mice, eliminating a relatively small proportion
(~30%) of senescent cells extends health span and prevents the
development of multiple age‐related morbidities in both progeroid
and normal, chronologically aged mice (Baker et al., 2011; Farr
et al., 2017; Ogrodnik et al., 2017; Roos et al., 2016; Schafer et al.,
2017; Xu et al., 2018). Moreover, late‐life clearance attenuated the
progression of already established age‐related disorders (Xu et al.,
2018). To be applicable to humans, Kirkland and collaborators have
identified a new class of drugs named senolytics in work that paral-
leled, but was not dependent on development of INK‐ATTAC mice.
Through exploiting senescent cells’ dependence on specific prosur-
vival pathways, senolytics specifically kill senescent cells without
affecting proliferating or quiescent, differentiated cells (Kirkland &
Tchkonia, 2015, 2017; Kirkland, Tchkonia, Zhu, Niedernhofer, &
Robbins, 2017). Recent studies have documented senolytic drugs
for the selective clearance of senescent cells from “aged” tissues,
which led to delayed acquisition of age‐related pathologies (Tchko-
nia & Kirkland, 2018). Recently, the Kirkland lab has demonstrated
that transplanting relatively small numbers of senescent preadipo-
cyte cells into young (6 month old) mice causes persistent physical
dysfunction, measured through maximal speed, hanging endurance
and grip strength, 1 month after transplantation. Transplanting even
fewer senescent cells into older (17 month old) recipients had the
same effect and reduced survival, indicating the potency of senes-
cent cells in shortening health‐ and lifespan. Intermittent oral
administration of the senolytics, dasatinib (D), a FDA‐approved tyro-
sine kinase inhibitor, and quercetin (Q), a flavonoid present in many
fruits and vegetables, to senescent cell‐transplanted young mice
and naturally aged mice alleviated physical dysfunction and
increased post‐treatment survival by 36% while reducing mortality
hazard to 65% (Xu et al., 2018). Altogether these data indicate that
cellular senescence is causally implicated in generating age‐related
phenotypes and that systemic removal of senescent cells can pre-
vent or delay tissue dysfunction, physical dysfunction and extend
health‐ and lifespan.
Like other organs, the adult mammalian heart has the capacity,
albeit low, to self‐renew cardiomyocytes over the human lifespan
(Bergmann et al., 2009), and genetic fate mapping models show that
one source of new cardiomyocytes is a population of resident stem
cells (Ellison et al., 2013; Hsieh et al., 2007). Multiple labs have
shown the mammalian heart, including human, to harbour self‐re-
newing, clonogenic, multipotent cardiac stem and progenitor cells
(CSCs or CPCs; abbreviated hereafter as CPCs) with regenerative
potential in vivo (Ellison‐Hughes & Lewis, 2017; Vicinanza et al.,
2017). An undisputed mechanism of action of CPC transplantation
into the infarcted myocardium is their secretome reparative poten-
tial, which through acting in a paracrine manner improves cardiomy-
ocyte survival, limits fibrosis, induces angiogenesis, new
cardiomyocyte formation and restores cardiac function (Broughton
et al., 2018).
Our lab has defined the CPC population to be Sca‐1pos/c‐kitpos/
CD31neg/CD45neg/Tryptaseneg (Ellison et al., 2013; Vicinanza et al.,
2017) distinguishing them from cardiac c‐kitpos endothelial (CD31pos)
and mast (CD45pos/Tryptasepos) cells. The CPCs are a rare population
in the adult heart, with ~1% evidencing cardiomyogenic regeneration
potential (Vicinanza et al., 2017). Recently, considerable confusion
has emanated over the significant cardiomyogenic potential of CPCs
purported using Kitcre knock‐in or dual recombinases‐mediated cell
tracking mouse models (Li et al., 2018; van Berlo et al., 2014). How-
ever, these models do not tag or specifically lineage trace the CPCs,
neither have the investigators isolated, characterized or transplanted
CPCs (according to the Sca‐1pos/c‐kitpos/CD31neg/CD45neg/
Tryptaseneg phenotype given above) from these mice to test their
stem cell and regenerative properties. Moreover, the c‐kitCre null
allele produced by Cre insertion fails to recombine the CPCs in the
Kitcre mice and there is a severe defect in CPC myogenesis pro-
duced by the c‐kit hemizygosity (Vicinanza et al., 2018).
Cardiac aging and pathology affects the activity and potency of
CPCs (Castaldi et al., 2017; Cesselli et al., 2011; Torella et al., 2004),
which translates into a diminished capacity of the aged and diseased
myocardium to maintain homoeostasis, and repair and regenerate
following injury (Ellison & Lewis 2017). The aging milieu might there-
fore limit the success of cell transplantation therapies where the out-
come is direct cardiogenic differentiation of transplanted cells and/or
stimulation of endogenous regenerative mechanisms. As the majority
of cardiovascular disease patients in need of regenerative therapies
are of advanced age, regulation of CPC and cardiovascular aging/se-
nescence is mission critical.
Here, we have carried out an extensive analysis of CPCs in the
human failing heart with advanced age and showed the accumulation
of senescent‐CPCs, which exhibit diminished self‐renewal, differenti-
ation and regenerative potential in vivo. We show that Senescent‐
CPCs have a SASP that negatively affects healthy non‐senescent,
cycling‐competent CPCs, rendering them senescent. Clearing the
senescent‐CPCs using senolytics attenuates the SASP and its effect
on promoting senescence in vitro. The effects of global elimination
of senescent cells on the heart and its regenerative capacity have
not been elucidated. We report novel data that show systemic
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elimination of senescent cells in vivo in aged mice using senolytics
(D + Q) or using the “suicide” transgene, INK‐ATTAC with adminis-
tration of AP20187, results in CPC activation and increased number
of small, immature, Ki67+ or EdU+ cardiomyocytes in the aged
mouse heart.
2 | RESULTS
2.1 | CPCs exhibit a senescent phenotype with
increased age
Human CPCs were isolated from biopsies of right atria, obtained
from subjects who had given informed consent before undergoing
cardiac surgery (aortic disease, valve disease, coronary artery bypass
graft (CABG) or multiple diseases), using sequential enzymatic diges-
tion and dissociation, Optiprep density gradient to remove large deb-
ris, followed by magnetic activated cell sorting (MACS) (Supporting
Information Figure S1a). CPCs were magnetically enriched based
upon a CD45‐negative, CD31‐negative, CD34‐negative and c‐kit‐
positive sorting strategy (Smith et al., 2014; Vicinanza et al., 2017)
(Supporting Information Figure S1b). Despite being recognized as a
CPC marker, cells were not sorted for Sca‐1 because its homology
has not been confirmed in any species other than mouse. By flow
cytometry analysis, CPCs showed expression of other recognized
CPC markers, such as CD90 (37 ± 0.4%), CD166 (41 ± 1%), CD105
(13 ± 1%) and CD140α (5 ± 0.4%) (Supporting Information Fig-
ure S1c). There were no differences in the number of CPCs isolated
from old (>70 years) subjects, compared to subjects <70 years. We
also found no differences in the number of CPCs isolated from male
or female, or from those subjects with valve disease, coronary dis-
ease or aortic disease (Supporting Information Figure S1d).
We isolated CPCs from 35 subjects of different genders, ages
and pathologies and found a linear increase (R2 = 0.722) in the num-
ber of freshly isolated CPCs that expressed the senescence‐associ-
ated marker, p16INK4A, with age (Figure 1a). No differences were
evident between males and females, smokers (including ex‐smokers)
and nonsmokers, diabetics and nondiabetics, and hypertensive and
nonhypertensive subjects for p16INK4A expression (Supporting Infor-
mation Figure S2a–d), and even though a trend was apparent, we
found no differences between aortic disease, valvular disease, coro-
nary artery disease and multiple other diseases for p16INK4A expres-
sion (Supporting Information Figure S2e). On average, 22 ± 9%,
31 ± 4%, 48 ± 9% and 56 ± 16% of freshly isolated CPCs expressed
p16INK4A isolated from 50–59, 60–69, 70–79 and 80–89 year old
subjects, respectively (Figure 1a). We also found an increase
(p < 0.05) in the number of senescence‐associated β‐galactosidase‐
(SA‐β‐gal; ~60%) and DNA damage marker, γH2AX‐positive CPCs
(~20%) freshly isolated from old (71–79 years), compared to middle‐
aged (54–63 years) subjects (Figure 1b,c). Moreover, p16INK4A‐posi-
tive CPCs co‐expressed γH2AX (Figure 1c). Further interrogation by
Q‐FISH revealed that, while the average telomere length of CPCs
freshly isolated from old and middle‐aged subjects’ hearts were com-
parable, CPCs freshly isolated from old (78–84 years) subjects’ hearts
contained a 12% subpopulation with telomere length of <6 kb,
which is regarded as being critically short (Figure 1d) (Canela, Vera,
Klatt, & Blasco, 2007). Approximately 2% of the CPCs freshly iso-
lated from human hearts were Ki67‐positive, reflective of their
mainly dormant, quiescent phenotype (Ellison et al., 2013). There
were no differences between middle‐aged and old subjects in num-
ber of Ki67‐positive CPCs, and we did not see any Ki67‐positive
CPCs that were p16INK4A‐positive (Supporting Information Fig-
ure S2f). These findings indicate that the aged human heart contains
an increased proportion of aged senescent‐CPCs, which could trans-
late to their dysfunctionality.
2.2 | CPCs from old subjects show impaired cell
growth and differentiation
CPCs were isolated from five old (76–86 years) and eight middle‐
aged (32–66 years) subjects, plated in growth medium, and propa-
gated, where possible, to passage 11. CPCs isolated from two of the
middle‐aged (32 and 61 years) and two of the oldest (78 and
80 years) subjects failed to grow and become established in vitro. Of
the CPC cultures that did grow from all age groups (n = 9), the
CPCs, from P3 to P11, gradually lost their p16INK4A–positive subpop-
ulation (Supporting Information Figure S2g), likely due to the cell cul-
ture activated, cycling‐competent CPCs outgrowing their p16INK4A–
positive senescent counterparts. CPCs maintained the phenotype of
c‐kit‐positive, CD31‐negative over culture passage (Supporting Infor-
mation Figure S2h). To ensure that the effect of donor age could be
effectively evaluated, all in vitro cell dynamic assays were performed
between P2‐P4.
CPCs isolated from old (77–86 years) subjects showed decreased
(p < 0.05) proliferation compared to CPCs isolated from middle‐aged
(34–62 years) subjects (Figure 2a). CPCs deposited as a single cell in
a 96‐well plate generated a greater number (p < 0.05) of clones if
the single CPCs originated from middle‐aged (34–62 years) subjects,
compared to old (76–86 years) subjects (Figure 2b). Likewise, CPCs
deposited at low dilution in bacteriological dishes for the generation
of spheres in suspension were greater in number and size (p < 0.05)
for middle‐aged (34–51 years) subjects’ CPCs, compared to old (76–
77 years) subjects’ CPCs (Figure 2c,d). When CPCs were plated in
cardiomyocyte differentiation medium, they primed towards a car-
diomyocyte‐like precursor cell type that was Nkx2.5‐positive, sar-
comeric actin‐positive and middle‐aged (47–62 years) subject's CPCs
had increased (p < 0.05) differentiation potential, compared to CPCs
from old (76–77 years) subjects (Figure 2e–g). Older subject's differ-
entiated CPC‐derived precursor cells showed disorganized sarcom-
eric structure (Figure 2e) and decreased (p < 0.05) expression
(Figure 2g), compared to differentiated CPCs from younger, middle‐
aged subjects.
Even though CPCs isolated from old hearts showed decreased
proliferation, clonogenicity and differentiation potential, only ~50%
of CPCs are senescent in old myocardium (Figure 1a); therefore,
these data imply that a functionally cycling‐competent CPC popula-
tion still exists in old myocardium. Indeed, single CPC‐derived clones
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from younger (22–33 years) and old (74–83 years) subjects were
indistinguishable in terms of morphology, senescence, multipotency,
self‐renewing transcript profile and differentiation (Supporting Infor-
mation Figure S3). These findings suggest that CPCs age and
become senescent in a stochastic, nonautonomous manner. This
resembles what was seen in rat preadipocytes (Kirkland, Hollenberg,
& Gillon, 1990).
2.3 | Aged‐senescent CPCs lose their regenerative
capacity in vivo
To purify for a senescent population of CPCs, we utilized the C12‐5‐
Dodecanoylaminofluorescein Di‐β‐D‐Galactopyranoside (C12FDG)
probe and sorted SA‐β‐gal‐positive CPCs through FACS (Supporting
Information Figure S4a–d). We also induced senescence in CPCs
pharmacologically using Doxorubicin and Rosiglitazone (Supporting
Information Figure S4e–g), which we have used previously to render
cells to senescence in vitro (Xu, Palmer, et al., 2015; Xu, Tchkonia,
et al., 2015; Xu et al., 2018). Senescent‐CPCs, whether Doxorubicin‐,
or Rosiglitazone‐induced and purified using the C12FDG probe,
exhibited a senescent phenotype being p16INK4A–positive, Ki67‐nega-
tive and with shorter telomeres (Supporting Information Figure S5).
Senescent SA‐β‐gal‐positive CPCs were nonproliferative and did not
form clonal colonies when deposited as single cells, or generate
spheres in vitro, compared to SA‐β‐gal‐negative, Ki67‐positive
cycling‐competent CPCs (Supporting Information Figure S5). FACS
phenotyping revealed decreased surface expression of the progenitor
markers, c‐kit, CD90, CD105 and CD166 and increased expression of
CD34 in SA‐β‐gal‐positive, senescent‐CPCs compared to SA‐β‐gal‐
negative, cycling‐competent CPCs (Supporting Information Figure S6).
To determine whether the dysfunctional stem/progenitor cell
properties of the senescent‐CPCs translated in vivo, we tested the
regenerative capacity of doxorubicin‐induced senescent SA‐β‐gal‐
positive CPCs and cycling‐competent SA‐β‐gal‐negative CPCs in the
myocardial infarction‐regeneration mouse model (Figure 3a). To sep-
arate the impact of senescence from other potentially confounding
aging processes operative in older mice, such as NAD deficiency,
accumulation of advanced glycation end products, or accumulation
F IGURE 1 Over half of cardiac
progenitor cells (CPCs) in the aged human
heart are senescent (a) Representative
immunofluorescence images and
quantification of c‐kitpos p16INK4Apos CPCs,
(n = 35 donors), (b) c‐kitpos SA‐β‐galpos
CPCs (*p = 0.0014; n = 2–4), (c) c‐kitpos γ‐
H2AXpos p16INK4A‐expressing CPCs
(*p = 0.0264; n = 5 donors). (d) Q‐FISH
telomere length of single c‐kitpos CPCs
(n = 100 cells per group, 20 cells per
donor). Representative
immunofluorescence images of telomere
staining, L5178Y‐S (10 kb) and L5178Y‐R
(79 kb) are mouse cell lines with known
telomere length. Frequency distribution
histogram of CPC telomere length (n = 5
donors/group). Nuclei stained in blue by
DAPI. All data are mean ± SEM
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of misfolded proteins, we transplanted senescent or cycling‐compe-
tent CPCs into young mice. Male, immunodeficient Nod‐SCID‐
Gamma (NSG) mice were subjected to permanent ligation of the left
anterior descending (LAD) coronary artery. Immediately after ligation,
5 × 105 SA‐β‐gal‐positive senescent or SA‐β‐gal‐negative cycling‐
competent CPCs were injected intramyocardially in 15µl of PBS at 2
sites in the border zone. To serve as a cell control, a separate set of
MI‐mice were injected with 5 × 105 non‐CPCs (c‐kitneg cardiac‐
derived cells; containing 86 ± 5% cardiac fibroblasts, 13 ± 3% vascu-
lar smooth muscle, 1 ± 1% endothelial cells (Ellison et al., 2013)). To
serve as a control, a separate set of MI‐mice were injected with
PBS. Sham animals were treated the same way, except ligation of
LAD coronary artery was not performed and they did not receive
cells but were injected with the same volume of PBS. Mice were
administered BrdU via osmotic mini pumps for 14 days after MI and
cell injection to track new cell DNA formation (Figure 3a). All cell
populations were labelled prior to injection with PKH26 lipophilic
membrane dye, which exhibited high labelling efficiency and label
dye retention over population doublings in cycling‐competent CPCs
and c‐kitneg cardiac‐derived cells in vitro (Supporting Information Fig-
ure S7). We sacrificed a subset of MI‐mice that had been injected
with 5 × 105 SA‐β‐gal‐negative cycling‐competent CPCs at 4 days.
There was high engraftment and survival of CPCs within the infarct/
border zone at 4 days (Figure 3b) and by 28 days the engraftment
was still ~10% of cycling‐competent CPCs per total nuclei in the
infarct/border zone (Figure 3c). The engraftment and survival of
senescent‐CPCs and c‐kitneg cells at 28 days was significantly
(p < 0.05) less (Figure 3c).
F IGURE 2 Cardiac progenitor cells
(CPCs) isolated from aged hearts exhibit
diminished proliferation, clonogenicity and
cardiomyocyte differentiation potential (a)
Quantification of CPC proliferation
(*p = 0.0266; n = 3–4 donors), (b) single
CPC‐derived clonal efficiency (*p = 0.0008,
n = 4–5 donors), (c) CPC spherogenesis
number (*p = 0.0051) and (d) size
(*p = 0.01), (n = 2–3 donors). (e)
Representative immunofluorescence
images of undifferentiated and
differentiated CPCs from old and middle‐
aged donors. Nuclei stained in blue by
DAPI. (f) Quantification of Nkx2.5pos
(*p = 0.0078; n = 3 donors) and (g) α‐
sarcomeric actin expression (*p = 0.0140;
n = 3 donors). All data are mean ± SEM
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(c)
(d)
(e)
(f) (g)
F IGURE 3 Aged‐senescent CPCs show decreased reparative potential (a) In vivo MI experimental design. (b) Representative confocal
images of PKH26pos CPCs engrafted in the myocardium 4 days post‐MI. (c) Quantification and representative confocal images of engraftment
of PKH26pos cells 28 days post‐MI (*p = 0.015 vs. c‐kitneg cells, n = 4–5 mice). (d) Echocardiography measurements of LV ejection fraction (EF),
fractional shortening (FS), left ventricular end‐diastolic diameter (LVEDD) and left ventricular end‐systolic diameter (LVESD) at baseline (BL)
before MI, 7 and 28 days after MI and cell injection (*p < 0.05 vs. Sham, †p < 0.05 vs. Cycling‐CPCs, Δp < 0.05 vs. dox‐induced Sen‐CPCs,
n = 5–7 mice). (e) Representative micrographs and quantification of average LV fibrosis (*p < 0.05 vs. Sham; †p = 0.0112 vs. Cycling‐CPCs;
n = 5–6 mice). (f) Representative confocal images of PKH26 co‐expression with α‐sarcomeric actinin and vWF (arrowheads) 28 days post‐MI.
(g) Quantification and representative confocal images of BrdUpos/α‐sarcomeric actininpos cardiomyocytes and BrdUpos/vWFpos capillaries
(*p < 0.05 vs. all; n = 5–7 mice). Nuclei stained in blue by DAPI. All data are mean ± SEM
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At 1 week after LAD ligation, all groups had decreased (p < 0.05)
LV function, compared to baseline and sham controls, however, the
group that had been injected with cycling‐competent CPCs had less
of a decrease in LV function at 1 week, compared to the senescent‐
CPC and non‐CPC c‐kitneg cell groups (Figure 3d). The degree of MI
represented as the % Average Area at Risk (AAR) through Evans
Blue staining immediately after MI was 33.0 ± 1.6% (n = 5), demon-
strating the operator as being extremely consistent in inducing a
similar size MI injury to each mouse. At 4 weeks after LAD ligation,
MI hearts that had received cycling‐competent CPCs showed an
improvement (p < 0.05) in LV ejection fraction (EF), fractional short-
ening (FS), left ventricular end diastolic diameter (LVEDD) and left
ventricular end systolic diameter (LVESD), which had almost returned
to baseline values and to that of Sham controls (Figure 3d).
This extent of LV improvement was not apparent in MI‐mice that
were injected with SA‐β‐gal‐positive senescent‐CPCs, PBS or the
non‐CPC c‐kitneg cell group that showed no recovery with worsened
LV function and were all in heart failure at 4 weeks (Figure 3d). To
accompany these functional changes, cycling‐competent CPC injec-
tion resulted in a decreased (p < 0.05) infarct size, whereas SA‐β‐gal‐
positive senescent‐CPCs, PBS or non‐CPC c‐kitneg cells did not
change the extent of infarct size (Figure 3e). Immunohistochemical
analysis of cross sections revealed that at 4 weeks after MI, the
transplanted PKH26‐labelled cycling‐competent CPCs had increased
expression of sarcomeric proteins, α‐actinin, as well as the endothe-
lial lineage marker vWF, evidencing their differentiation into car-
diomyocyte‐like precursor cells and endothelial cells, respectively
(Figure 3f; Supporting Information Figure S8a,b). Limited or no differ-
entiation was evident in the infarcted/border zone of the hearts
injected with PKH26‐labelled senescent‐CPCs and non‐CPC c‐kitneg
cells (Figure 3f). To determine whether the transplanted cells had
participated in inducing a paracrine effect, the infarct/border zone of
hearts that had received cells were analysed for formation of new
cells that were BrdU‐positive/PKH26‐negative. Hearts that were
injected with cycling‐competent CPCs showed an increased number
of BrdU‐positive cells, compared to those injected with SA‐β‐gal‐pos-
itive senescent‐CPCs or non‐CPC c‐kitneg cells (Supporting Informa-
tion Figure S8c,d). Moreover, these BrdU‐positive cells co‐localized
with vWF or α‐sarcomeric actinin, indicating that these endothelial
(capillary) cells and cardiomyocytes had been prompted to initiate
DNA synthesis and suggest they may have entered the cell cycle.
BrdU‐positive cardiomyocyte and capillaries were more evident
(p < 0.05) in the MI‐cycling‐competent CPC group (Figure 3g). These
findings show the diminished regenerative and reparative capacity of
senescent CPCs, compared to healthy, cycling‐competent CPCs.
2.4 | Aged‐senescent CPCs have a senescence‐
associated secretory phenotype (SASP)
Senescent cells exhibit a SASP (Tchkonia et al., 2013). Dox‐in-
duced senescent SA‐β‐gal‐positive CPCs showed increased expres-
sion of SASP factors, including MMP‐3, PAI1, IL‐6, IL‐8, IL‐1β and
GM‐CSF, compared to nonsenescent, SA‐β‐gal‐negative, cycling‐
competent CPCs (Figure 4a). To determine whether the SASP fac-
tors were secreted from senescent‐CPCs, we quantified the pro-
tein levels of seven of the highly expressed SASP factors in
conditioned media from senescent‐CPCs using Luminex technology.
We found increased (p < 0.05) quantities of all seven SASP fac-
tors in senescent‐CPC conditioned medium, compared to condi-
tioned medium of cycling‐competent CPCs (Figure 4b). Next, we
treated cycling‐competent CPCs with conditioned medium (CM)
from senescent‐CPCs and measured cell proliferation and senes-
cence of the cycling‐competent CPCs. Conditioned medium from
senescent‐CPCs resulted in decreased (p < 0.05) proliferation (Fig-
ure 4c) and an increased (p < 0.05) proportion of senescent
p16INK4A–positive, SA‐β‐gal‐positive and γH2AX‐positive CPCs in
the cultures, compared to CPCs treated with CM from cycling‐
competent CPCs or unconditioned medium (UM) (Figure 4d–f).
These findings show that the senescent‐CPCs exhibit a SASP,
which can negatively impact surrounding cells, rendering otherwise
healthy, cycling‐competent CPCs to lose proliferative capacity and
switch to a senescent phenotype. This is consistent with the
spread of senescence to recipients’ cells that we observed after
transplanting another senescent progenitor cell type, senescent
adipocyte progenitors (Xu et al., 2018).
2.5 | Elimination of senescent CPCs using senolytic
drugs abrogates the SASP in vitro
Removal of p16Ink4a senescent cells can delay the acquisition of age‐
related pathologies in adipose tissue, skeletal muscle, heart, blood
vessels, lung, liver, bone and eye (Baker et al., 2016, 2011; Farr
et al., 2017; Lehmann et al., 2017; Ogrodnik et al., 2017; Roos et al.,
2016; Schafer et al., 2017; Xu, Palmer, et al., 2015; Xu, Tchkonia,
et al., 2015; Xu et al., 2018; Zhu et al., 2015). Recent studies have
documented the use of senolytic drugs for the selective clearance of
senescent cells from “aged” tissues (Tchkonia & Kirkland, 2018). We
tested the potential of four senolytic drugs, Dasatinib (D; an FDA‐
approved tyrosine kinase inhibitor), Quercetin (Q; a flavonoid present
in many fruits and vegetables), Fisetin (F; also a flavonoid) and Navi-
toclax (N; an inhibitor of several BCL‐2 family proteins), alone and in
combination to eliminate and clear senescent‐CPCs in vitro (Support-
ing Information Figure S9). Measuring cell viability with crystal violet
and the number of SA‐β‐gal‐positive CPCs, dose–response experi-
ments on senescent‐ or cycling‐competent CPCs from the same sub-
jects showed D and N to effectively clear senescent‐CPCs, whereas
F and Q were less effective (Supporting Information Figure S9b,c).
However, D also decreased the viability of cycling‐competent CPCs
(Supporting Information Figure S9b). A combination of D + Q, which
has previously shown to yield effective senescent cell clearance (Farr
et al., 2017; Lehmann et al., 2017; Ogrodnik et al., 2017; Roos et al.,
2016; Schafer et al., 2017; Xu et al., 2018; Zhu et al., 2015) and
which does not share the toxic anti‐neutrophil and anti‐platelet side
effects of N (Kirkland & Tchkonia, 2015; Kirkland & Tchkonia, 2017)
was tested, and at a dose of 0.5 µM D with 20 µM Q, cycling‐com-
petent CPC viability was preserved (Figure 5a) while senescent‐CPCs
LEWIS‐MCDOUGALL ET AL. | 7 of 15
F IGURE 4 Aged‐senescent CPCs have a SASP (a) Transcript SASP factor expression of dox‐induced Sen‐CPCs relative to Cycling‐CPCs
(control). (b) SASP factor protein levels quantified by Luminex of unconditioned media (UM), Cycling‐CPC (CM) and dox‐induced Sen‐CPC (Sen
CM) conditioned media (*p < 0.05 vs. UM and CM). Conditioned media applied to cycling‐competent CPCs and the following analyses
performed; (c) Quantification and representative staining of CPC proliferation (*p < 0.001; n = 5 replicates), (d) p16INK4A‐pos CPCs (*p < 0.0001;
n = 5 replicates), (e) SA‐β‐galpos CPCs (*p < 0.0001; n = 5 replicates), (f) γH2AXpos CPCs (*p < 0.001; n = 5 replicates). All data are mean ± SEM
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were cleared and induced to selective apoptosis (Supporting Infor-
mation Figure S9d).
We next determined whether clearing senescent‐CPCs using
D + Q would abrogate the SASP and its paracrine impact on
CPCs. Using transwell inserts, cycling‐competent CPCs were
seeded on the top chamber insert and co‐cultured in the presence
of senescent‐CPCs seeded on the bottom chamber. Cultures were
left for 7 days, and then cycling‐competent CPCs in the top cham-
ber were analysed for viability, proliferation and markers of senes-
cence, p16INK4A, SA‐β‐gal and γH2AX, and conditioned medium
analysed for SASP factors. The cultures were then treated with
D + Q for 3 days to clear the senescent‐CPCs on the bottom
chamber, and then 7 days later cycling‐competent CPCs in the top
chamber were analysed for viability, proliferation and the markers
of senescence, p16INK4A, SA‐β‐gal and γH2AX, and conditioned
medium analysed for SASP factors (total of 17 days; Supporting
Information Figure S9a). We found that cycling‐competent CPCs
co‐cultured in the presence of senescent‐CPCs for 7 days were
decreased (p < 0.05) in number and proliferation and had
increased (p < 0.05) expression of p16INK4A, SA‐β‐gal and γH2AX
(Figure 5b–f). Application of D + Q to co‐cultures eliminated the
senescent‐CPCs (Figure 5g) and 7 days later, the cycling‐competent
CPCs had increased (p < 0.05) in number (Figure 5h), proliferation
(Figure 5i), and the number of p16INK4A and SA‐β‐gal CPCs had
decreased (p < 0.05) compared to CPCs that had been in co‐cul-
ture with senescent‐CPCs for 17 days (Figure 5j,k). Co‐culture of
cycling‐competent CPCs with senescent‐CPCs led to increased
(p < 0.05) secretion of SASP factors into the medium, but the
level of SASP factors was reduced (p < 0.05) with application of
D + Q (Figure 5l). These findings document that senescent
CPCs have a SASP, and clearance of senescent CPCs using a
combination of D + Q senolytics abrogates the SASP and its detri-
mental senescence‐inducing effect on healthy, cycling‐competent
CPCs.
2.6 | Elimination of senescent cells in vivo activates
resident CPCs and increases number of small,
proliferating cardiomyocytes in the aged heart
To determine the effects of global senescent cell removal on the
heart, 24–32 month INK‐ATTAC transgenic or wild‐type mice were
randomised to either vehicle, AP20187, or D + Q treatment, admin-
istered in 4 cycles for 3 consecutive days/cycle, 12 days apart. Mice
were sacrificed 4 days after the last dose of cycle 4 (Figure 6a). Tis-
sues in which p16Ink4a expression and/or senescent cells are
decreased by D + Q in wild‐type mice as well as by AP20187 in
INK‐ATTAC mice include the aorta, adipose tissue, cardiac and skele-
tal muscle, lung, liver and bone (Baker et al., 2016; Farr et al., 2017;
Lehmann et al., 2017; Ogrodnik et al., 2017; Roos et al., 2016; Scha-
fer et al., 2017; Xu et al., 2018; Zhu et al., 2015). We showed
p16Ink4a mRNA expression was decreased (p < 0.05) in the heart fol-
lowing D + Q or AP20187 treatment in aged INK‐ATTAC or wild‐
type mice (Figure 6b).
Previously, we have shown an improvement of heart function
in old mice after D + Q treatment (Zhu et al., 2015). Analysis of
cardiac cross sections revealed significantly higher (p < 0.05) CPC
(Sca‐1+/c‐kit+/CD45−/CD31−/CD34−) numbers (Figure 6c; Support-
ing Information Figure S10a) in AP20187‐treated INK‐ATTAC mice
and D + Q‐treated INK‐ATTAC or wild‐type mice, compared to
vehicle‐treated control. Interestingly, D + Q treatment showed
increased (p < 0.05) CPC number, compared to AP20187‐treatment
(Figure 6c). Roughly 10% of CPCs were activated and in the cell
cycle (Ki67‐positive) at the time of sacrifice, after AP20187 or
D + Q treatment (Supporting Information Figure S10b). Morpho-
metric analysis of heart sections showed that AP20187‐treated
and D + Q‐treated mice had increased number of smaller ventricu-
lar myocytes (Figure 6d), suggesting these myocytes to be imma-
ture and newly formed, compared to vehicle‐treated mice, which
exhibited only rare small myocytes but a greater proportion of
hypertrophied myocytes (Figure 6d). We found an increase
(p < 0.05) of small, proliferating Ki67‐positive myocytes (~0.25%)
in old hearts following AP20187‐ or D + Q‐treatment, compared
to vehicle‐treated control (0.03 ± 0.03%) (Figure 6e,f). To corrobo-
rate these data, we injected EdU 4 days and 2 hr prior to sacrifice
of old (22 months) and young (3 months) AP20187‐treated INK‐
ATTAC mice (Supporting Information Figure S10c). We found
increased (p < 0.05) number of small EdU‐positive myocytes
(0.25 ± 0.06%; Figure 6g,h) in the hearts of old AP‐treated mice,
compared to old vehicle‐treated (0.07 ± 0.00%), young vehicle‐trea-
ted (0.12 ± 0.03%) and young AP‐treated (0.11 ± 0.04%) mice. The
number of EdU‐positive myocytes in the old AP‐treated INK‐
ATTAC mice was the same in amount to Ki67‐positive myocytes
(~0.25%) in AP20187‐ or D + Q‐treated mouse hearts (Figure 6f).
Finally, we detected a decrease (p < 0.05) in fibrosis in the LV fol-
lowing AP20187‐ and D + Q‐treatment, compared to vehicle‐trea-
ted control (Figure 6i). In contrast to the treatment of aged mice,
treatment of young adult (2–3 months) INK‐ATTAC or wild‐type
mice with AP20187 or D + Q, respectively, did not alter EdU‐posi-
tive myocyte number (Figure 6h), CPC numbers or myocyte diame-
ter (data not shown). These findings show that clearance of
senescent cells leads to stimulation of CPCs and cardiomyocytes
with increased DNA‐synthesizing activity and that this strategy is
specific to the aged heart.
3 | DISCUSSION
Our study shows that CPCs isolated from the failing human heart
develop a senescent phenotype with age exhibited by increased
expression of senescence‐associated markers (p16INK4A, SA‐β‐gal),
DNA damage, shortened telomere length and a SASP. Aged human
hearts with dilated cardiomyopathy showed greater numbers of
p16INK4A –positive CPCs and cardiomyocytes with shorter telomeres
than age‐matched controls (Chimenti et al., 2003). Similarly, CPCs
isolated from failing, aged hearts show increased p16INK4A and
inflammatory factor expression (Cesselli et al., 2011). Reliably detect-
ing senescent cells in vivo is an ongoing challenge, and it is
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F IGURE 5 Senolytic clearance abrogates the SASP (a) Viability (Crystal violet) and SA‐β‐gal quantification of dox‐induced Sen‐CPCs and
Cycling‐CPCs exposed to various concentrations of D + Q for 3 days. (b–f) Quantification of 7 days of co‐culture of Cycling‐CPCs with dox‐
induced Sen‐CPCs for (b) viability (*p = 0.0068); (c) proliferation (*p = 0.0056); (d) p16INK4A (*p = 0.0025); (e) SA‐β‐gal (*p = 0.0025); (f) γH2AX
(*p = 0.0002). CTRL is Cycling‐ CPCs alone. (n = 5 replicates). (g) Representative SA‐β‐gal staining after clearance of dox‐induced Sen‐CPCs
from co‐culture by D + Q treatment. (h–k) Quantification of 17 days of co‐culture of Cycling‐CPCs with dox‐induced Sen‐CPCs or co‐culture
with D + Q treatment for (h) viability (*p < 0.0001 vs. CTRL 17 days; †p = 0.0001 vs. co‐culture 17 days); (i) proliferation (*p < 0.0001 vs.
CTRL 17 days; †p < 0.0001 vs. co‐culture 17 days); (j) p16INK4A (*p < 0.0001 vs. CTRL 17 days; †p < 0.0001 vs. co‐culture 17 days) and (k)
SA‐β‐gal (*p < 0.0001 vs. CTRL 17 days; †p < 0.0001 vs. co‐culture 17 days). CTRL is Cycling‐CPCs alone. (n = 5 replicates). (l) SASP factor
protein levels quantified by Luminex from each treatment condition (*p < 0.0001 vs. CTRL; †p < 0.01 vs. co‐culture 7 days and 17 days).
(n = 2 replicates). All data are mean ± SEM
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important that a combination of senescent cell biomarkers is used
for detection as any one marker used in isolation is prone to false
positives. Our study used a combined panel of the senescence‐asso-
ciated biomarkers, p16INK4A, γH2AX, telomere length, SA β‐gal activ-
ity and SASP expression, to detect senescent CPCs. A limitation of
our study is that because of low yield of CPCs isolated from small
myocardial samples (~45,000 per gram of tissue) we were unable to
evaluate the expression of SASP factors on freshly isolated CPCs, or
test the effects of the SASP of freshly isolated CPCs in vitro. Our
findings demonstrate that CPCs accumulate in the failing hearts of
elderly subjects (>70 years) and are dysfunctional, showing impaired
proliferation, clonogenicity, spherogenesis and differentiation, com-
pared to CPCs isolated from the hearts of middle‐aged (32–66 years)
subjects. As the adult heart possesses very low numbers (<1% of c‐
F IGURE 6 Clearance of senescent cells stimulates new cardiomyocyte formation in the aged heart (a) In vivo senescent cell clearance
experimental design. (b) Total cardiac p16Ink4a gene expression following clearance (*p < 0.01 vs. Vehicle; n = 5 mice). (c) Quantification of
CPCs following clearance, (*p < 0.0001 vs. Vehicle; †p = 0.0453 vs. AP; n = 10–11 mice). (d) Frequency distribution histogram of
cardiomyocyte diameter, (n = 6 mice). (e) A Ki67pos/α‐sarcomeric actinpos cardiomyocyte (arrowhead) in the LV of a 32 month D + Q‐treated
mouse. (f) Quantification of Ki67pos cardiomyocytes, (*p < 0.0001 vs. Vehicle; n = 10 mice). (g) An EdUpos/α‐sarcomeric actinpos cardiomyocyte
in the LV of a 22 month INK‐ATTAC AP‐treated mouse. Nuclei are stained by DAPI in blue. (h) Quantification of EdUpos cardiomyocytes
(*p < 0.0001 vs. Old + Vehicle; †p < 0.0001 vs. Young + AP; n = 5 mice). (i) Quantification of LV fibrosis (*p < 0.05 vs. Vehicle; n = 3 mice).
All data are mean ± SD
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kitpos cells) of cardiomyogenic CPCs (Vicinanza et al., 2017), if by
80 years of age >50% of resident CPCs are senescent, this presents
a bleak outcome for harvesting healthy, functional CPCs from
patients who are candidates for regenerative therapies and their
autologous use. Moreover, strategies to activate the regenerative
capacity of the aged heart through delivery of growth factors or cell
therapy will also be suboptimal. Therefore, the success of cardiac
regenerative therapeutic approaches thus far tested for treating
patients with heart failure and disease could be of limited efficacy in
promoting myocardial regeneration because of the increased number
of senescent, dysfunctional CPCs and cardiomyocytes (Cesselli et al.,
2011; Chimenti et al., 2003), and the resultant presence of a cardiac
SASP in the aged and failing heart that impairs the function of the
remaining nonsenescent CPCs. These findings may also have implica-
tions regarding the use hearts from aged versus younger donors for
transplantation (Lau, Kennedy, Kirkland, Tullius, & S.G., 2019).
The present study found that CPCs age in a stochastic nonau-
tonomous manner, and it is possible to clonally select from a single
CPC for a cycling‐competent population of CPCs even from diseased
or aged hearts. There are individual CPCs in older individuals that
have replicative and functional capacities resembling those of CPCs
in younger subjects. A similar scenario was found in the case of rat
fat cell progenitors (Kirkland et al., 1990). While the abundance of
progenitors cloned from adipose tissue that had restricted capacities
for replication and differentiation into adipocytes or that were non-
replicative but viable (i.e., senescent) increased progressively with
aging in rat adipose, there remained cells that had the capacities for
replication and adipogenic differentiation characteristic of clones
derived from young rats. In the present study, we utilized hypoxic
conditions (5% CO2, 2% O2) to expand viable CPCs. Other interven-
tional approaches have shown that senescence characteristics of
human CPCs are alleviated by Pim‐1 kinase resulting in rejuvenation
of CPC phenotypic and functional properties (Mohsin et al., 2013).
Together, these findings indicate that: (a) it may be feasible to isolate
and propagate CPCs even from older individuals that are functional,
capable of supporting cardiac regeneration if removed from their
toxic milieu, and that could be therapeutically relevant in treating
patients, especially if they were autologously generated and (b) that
by clearing senescent CPCs with a toxic SASP from the aged heart,
there remains a tissue‐resident population of CPCs with regenerative
and reparative potential.
When we purified for a homogenous SA‐β‐gal‐positive, senescent
CPC population, we showed that these cells had poor engraftment
and survival and were unable to contribute to cardiac regeneration,
repair or restoration of cardiac function following transplantation
into the infarcted myocardium. This is contrary to in vitro‐selected,
SA‐β‐gal‐negative, proliferative cycling‐competent (Ki67pos) CPCs,
which had high survival and engraftment in the infarct/border zone,
restored cardiac function almost to baseline and sham control values
(LVEF 59 ± 2% at 28 days vs. 66 ± 2 at baseline), decreased infarct
size, differentiated into endothelial and cardiomyocyte‐like precursor
cells as well as enhanced endogenous BrdUpos cardiomyocytes and
capillaries. Although some of the transplanted CPCs expressed α‐
sarcomeric actin, these cells did not exhibit the typical cardiomy-
ocyte phenotype as they were small and lacked a structured sarcom-
eric unit. Therefore, they could not be considered as new, immature
myocytes that contributed physiologically to the substantially
improved LV function. There is now a general consensus that the
favourable effect of cell transplantation protocols is, at least in part,
mediated by “paracrine” effectors secreted by the transplanted cells,
contributing to improved myocardial contractility and amelioration of
ventricular remodelling (decreasing fibrosis, hibernation, and stun-
ning), inhibition of the inflammatory response, and increased car-
diomyocyte survival, cardiomyogenesis and angiogenesis/
neovascularisation (Broughton et al., 2018). The present data empha-
size the importance of taking into account the hostile infarcted envi-
ronment, which does not favour engraftment, differentiation or
maturation of newly formed cardiomyocytes derived from injected
cells. However, the presence of CPC‐derived cardiomyocyte precur-
sors expressing sarcomeric protein in the infarct/border zone is
promising, and further work should elucidate how to mature these
cells into functionally competent contractile cells.
Like the present study, not all experimental studies have shown
physiological regeneration of CPC‐derived cardiac muscle following
administration of CPCs (Tang et al., 2016). This is most likely due to
the heterogeneous nature of cardiac c‐kit positive cells tested, with
only a very small fraction (1%–2%) having properties of cardiomyo-
genic stem cells (Vicinanza et al., 2017). However, bringing together
the cardiomyogenic potential of CPCs, which can be amplified in
number through in vitro single cell‐derived clonal selection, and
CPC‐mediated cytokine release, advocate CPCs as an ideal candidate
for cardiac regenerative interventions.
Senescent cells have emerged as bona fide drivers of aging and
age‐related CVD, which suggests strategies aimed at reducing or
eliminating senescent cells could be a viable target to treat and pre-
vent CVD (Childs, Li, & Deursen, 2018). In 18‐month‐old INK‐ATTAC
mice, p16INK4a‐positive cells contribute to cardiac aging and these
senescent cells decreased following AP20187‐treatment (Baker et al.,
2016). Moreover, D + Q administration over 3 months decreased
senescent cell markers (TAF + cells) in the media layer of the aorta
from aged (24 months) and hypercholesterolemic mice, which was
met with improved vasomotor function (Roos et al., 2016). We show
for the first time that the genetic and pharmacological approaches
used here to reduce senescent cell burden leads to increased num-
ber of CPCs and smaller ventricular myocytes, which were Ki67‐pos-
itive and EdU‐positive, suggesting these myocytes to be immature
and newly formed (Ellison et al., 2013), compared to vehicle‐treated
mice, which exhibited very rare small myocytes but a greater propor-
tion of hypertrophied myocytes. These findings are in line with those
of Baker et al. (2016) who showed that AP‐treated INK‐ATTAC mice
had smaller ventricular cardiomyocytes.
The frequency of resident cardiac stem and progenitor cells in
the healthy myocardium of several mammalian species, including
human, mouse, rat and pig, is approximately one per every 1,000–
2,000 myocytes, depending on age (Torella, Ellison, Karakikes, &
Nadal‐Ginard, 2007). We detected a 16‐ and 23‐fold increase in the
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number of CPCs following elimination of senescent cells by AP‐ or
D + Q‐treatment in the aged mouse heart, respectively. Moreover,
~10% of CPCs after elimination of senescent cells were activated,
expressing Ki67. The number of Ki67‐positive and EdU‐positive car-
diomyocytes increased nine‐ and four‐fold in the aged heart, respec-
tively, following clearance of senescent cells by either D + Q‐ or AP‐
treatment. We show that the number of DNA‐synthesizing car-
diomyocytes present in the young (3 months old) mouse heart is
0.12 ± 0.03% of total cardiomyocytes, and the number of DNA‐syn-
thesizing cardiomyocytes present in the old (22 months old) mouse
heart is 0.07 ± 0.00% of total cardiomyocytes. Elimination of senes-
cent cells lead to double the amount of DNA‐synthesizing cardiomy-
ocytes found in a young heart and triple the number found in an old
heart. Therefore, the present data represent a significant and physio-
logically relevant increase and activation of the resident CPC com-
partment and increased cardiomyocyte DNA synthetic activity
following clearance of senescent cells. These findings are consistent
with the hypothesis that clearing senescent cells can beneficially
alter stem and progenitor cell function across multiple tissues.
D + Q enhances function of osteoblastic progenitors, leading to new
bone formation in mice with age‐related osteoporosis, impedes func-
tion of the osteoclast progenitors that lead to bone resorption in
these same mice (Farr et al., 2017), and enhances neurogenesis in
mice with metabolically induced impairment of nerve cell generation
(Ogrodnik et al., 2019).
Previous work has shown that senescent human primary prea-
dipocytes, human omental adipose tissue cells obtained from
obese individuals (45.7 ± 8.3 years), as well as human umbilical
vein endothelial cells (HUVECs) develop a SASP with aging, which
induced inflammation in healthy adipose tissue and preadipocytes
(Xu, Palmer, et al., 2015; Xu, Tchkonia, et al., 2015; Xu et al.,
2018). Clearance of senescent cells using D + Q decreased the
secretion of key SASP components, PAI‐1, GM‐CSF, IL‐6, IL‐8 and
MCP‐1 (Xu et al., 2018). In the present study, clearance of senes-
cent human CPCs using D + Q abrogated the SASP and the dele-
terious impact of the SASP on CPC proliferation and inducing
senescence. Thus, D + Q can kill human senescent cells, including
tissue‐specific stem/progenitor cells, and can attenuate the secre-
tion of inflammatory cytokines associated with human age‐related
frailty (Xu et al., 2018). Consistent with this, in the first human
trial of senolytics, subjects with idiopathic pulmonary fibrosis had
enhanced walking endurance, gait speed, chair rise test perfor-
mance and scores in the Short Physical Performance Battery
5 days after nine doses of D + Q over 3 weeks (Justice et al.,
2019).
In conclusion, the present work, albeit performed in mouse
models, demonstrates approaches that eliminate senescent cells
may be useful for treating age‐related cardiac deterioration and
rejuvenating the regenerative capacity of the aged heart. However,
caution should be exercised in interpreting mouse data considering
previous cardiac regenerative strategies where bone marrow
derived cells injected into mouse MI models did not translate into
equivalent outcomes in humans. Future work should address the
effects of senolytic agents on improving cardiac function and alle-
viating the SASP, resulting in an improved microenvironment
in vivo and the activity of other cell types, such as fibroblasts and
endothelial cells. Indeed, next steps should determine whether
senolytic approaches could be used in conjunction with cell ther-
apy interventions to improve the environment (the “soil”) that the
cells (the “seeds”) are transplanted into and therefore, ameliorate
intrinsic reparative mechanistic processes that are compromised
with age (Lau et al., 2019). Indeed, targeting senescent cells could
also impact the potency of resident stem/progenitor populations in
other aged organs. The present findings provide new insights into
therapies that target senescent cells to prevent an age‐related loss
of regenerative capacity.
4 | EXPERIMENTAL PROCEDURES
4.1 | Expanded experimental procedures are in the
supporting information
Myocardial samples (~200 mg each) were obtained from the right atrial
appendage (total samples, n = 119) of human subjects with cardiovas-
cular disease, aged 32–86 years. Subjects aged 70–86 years were
included in the old group. Subjects aged 32–67 years were included in
the middle‐aged group. All subjects gave informed consent before tak-
ing part in the study (NREC #08/H1306/91). Cardiac tissue was minced
and enzymatically digested to release cardiac small cells. CPCs were
purified by first depleting CD45pos and CD31pos cells by immunola-
belling with anti‐human CD45 and CD31 magnetic immunobeads (Mil-
tenyi), and then the CD45‐ CD31‐depleted fraction was enriched for c‐
kitpos cells through incubation with anti‐human CD117 immunobeads
(Miltenyi). CPCs were characterized by flow cytometry for other CPC
markers before proceeding with functional in vitro and in vivo assays.
All animal surgical experiments were conducted in accordance with the
regulations of the Home Office and stipulated under the Animals (Sci-
entific Procedures) Act 1986.
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